11
Received first-line
immunotherapy
Received first-line
combination immunotherapy
+ chemotherapy
No standard algorithm; consider
any single-agent chemotherapy
option not received in first-line
a
Driver alterations including EGFR, ALK, ROS-1, BRAF V600E, MET exon 14, NTRAK,
KRAS, and RET.
S
Standard non-platinum-
based chemotherapy
(if platinum is contraindicated)
S
Standard platinum-based
chemotherapy
Strength of
Recommendation
W
Strong
Moderate
Weak
M
S
